Skip to main content

Table 2 The distribution of EMG-NCV (Median and IQR) in each group of study

From: Lithium and preventing chemotherapy-induced peripheral neuropathy in breast cancer patients: a placebo-controlled randomized clinical trial

Variable

Group

Start time

Median (IQR)

3rd month

Median (IQR)

9th month

Median (IQR)

P

Ulnar NCV

Drug

65 (9)

42.5 (15.3)

55 (17)

< 0.001

Placebo

68.5 (5)

40 (17.8)

52 (18.5)

< 0.001

Ulnar Amp

Drug

6.1 (1)

3 (2)

5.4 (1.2)

< 0.001

Placebo

6.4 (1)

4 (1.5)

5 (2)

< 0.001

Median NCV

Drug

60 (18.5)

40 (18.5)

50 (14.5)

< 0.001

Placebo

60.5 (10)

39 (17.5)

49.5 (18.3)

< 0.001

Median Amp

Drug

5.2 (1.4)

2.9 (2.1)

4.1 (2)

< 0.001

Placebo

5 (1.6)

2.3 (2)

4.3 (2.3)

< 0.001

Tibial NCV

Drug

53.5 (10)

36.5 (16.5)

45.5 (8.3)

< 0.001

Placebo

55 (7.5)

34.5 (19.3)

47.5 (13.3)

< 0.001

Tibial Amp

Drug

3 (0.1)

1.9 (1.3)

2.4 (0.8)

< 0.001

Placebo

3 (0.2)

1.8 (1.2)

2.5 (1)

< 0.001

Proneal NCV

Drug

54 (11.5)

35 (13.3)

42.5 (12.5)

< 0.001

Placebo

54.5 (10.8)

32 (11.5)

43.5 (15.9)

< 0.001

Proneal Amp

Drug

3 (0.3)

1.9 (1.3)

2.3 (0.7)

< 0.001

Placebo

3 (0.1)

1.9 (0.9)

2.1 (1)

< 0.001

  1. NCV nerve conduction velocity, Amp amplitude